Institution
Shriners Hospitals for Children - Galveston
Healthcare•Galveston, Texas, United States•
About: Shriners Hospitals for Children - Galveston is a healthcare organization based out in Galveston, Texas, United States. It is known for research contribution in the topics: Burn injury & Lean body mass. The organization has 249 authors who have published 420 publications receiving 15311 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Results indicate that PMN‐II appearing in association with burn injury contribute to the decreased production of HBDs in thermally injured patients.
Abstract: Immunosuppressive neutrophils (PMN-II) appearing in association with burn injury have a role on the increased susceptibility of burn patients to various infections. In the present study, the role of PMN-II on the production of human β-defensins (HBDs), important molecules on host antimicrobial innate immunities, by human keratinocytes was studied. Normal human epidermal keratinocytes (NHEKs) were cultured with neutrophils (PMNs) isolated from burn patients or healthy volunteers in dual-chamber transwells. Culture fluids harvested 24 h after cultivation were assayed for HBDs using enzyme-linked immunosorbent assay. Also, these culture fluids were assayed for their antimicrobial activities by a standard colony-counting method using Pseudomonas aeruginosa. In the results, PMNs isolated from peripheral blood of burn patients were confirmed as PMN-II, because these cells produced CC-chemokine ligand 2 (CCL2), but not interleukin (IL)-12 and CC-chemokine ligand 3 (CCL3). Culture fluids of NHEK transwell-cultured with healthy PMNs exhibited strong killing activities against P. aeruginosa (96% inhibition), however, the growth of bacteria was not dramatically inhibited by the culture fluids of NHEK transwell-cultured with burn-patient PMNs (36% inhibition). IL-12 and CCL3 containing culture fluids of healthy PMNs stimulated with the bacterial antigen or rCCL3 and rIL-12 enhanced the production of HBD2 and HBD3 by NHEK, whereas CCL2 containing culture fluids of burn-patient PMN stimulated with the antigen or rCCL2 inhibited the HBD production by NHEK. These results indicate that PMN-II appearing in association with burn injury contribute to the decreased production of HBDs in thermally injured patients.
4 citations
••
TL;DR: A response to the letter by Drs.
Abstract: We thank the Editor for inviting us to write a response to the letter by Drs. Dela and Helge (1) concerning our recent article in Diabetes (2). The authors draw our attention to an incorrect reference used to describe mitochondrial respiration measurements. The correct reference is an article that Dr. Dela’s group published in 2010 (3). We apologize for any confusion caused. We hope this alleviates the authors’ concerns on the methodology used for the mitochondrial respiration measurements; nevertheless, we provide further information here for clarity. Biopsies were immediately submerged in preservation buffer (BIOPS as described in ref. 3) and immediately (within 30 min) brought to the laboratory. …
4 citations
••
TL;DR: Oxandrolone coadministration does not alter propranolol’s plasma concentration, half-life, or effect on heart rate, and maximum and minimum proPRanolol plasma concentrations were similar with either dosing regimen.
Abstract: The systemic impact of severe burn injury results in a variety of disorders that require therapeutic intervention. Propranolol, a nonselective β1, β2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines. Oxandrolone, a testosterone mimetic, promotes protein synthesis and anabolism to counter muscle wasting. Coadministration of these drugs is expected to synergistically improve patient outcomes. Testosterone administration is known to alter β-adrenergic receptor-mediated signaling. Here, we determined whether the coadministration of oxandrolone alters plasma propranolol concentrations. Ninety-two pediatric patients with burns covering ≥30% of the TBSA were enrolled in this institutional review board-approved study and randomized to receive propranolol (n = 49) or oxandrolone + propranolol (n = 43). Plasma propranolol concentrations were determined following two dosing strategies: Q6 (liquid formulation; n = 86) and Q24 (extended-release capsule; n = 22). Samples were drawn before drug administration and at regular intervals throughout the next two dosing periods. Heart rate and blood pressure were recorded throughout the study. Propranolol half-life was 3.3 hours for the Q6 drug dosing frequency (P < .0001) and 11.2 hours for the Q24 strategy (P < .0001). Percentage of predicted heart rate declined by 2.8% for each doubling of the propranolol concentration in the Q6 dosing schedule (P < .0001). Percentage of predicted heart rate declined by 2.5% for each doubling of propranolol concentration on the Q24 dosing schedule (P < .0001). Maximum and minimum propranolol plasma concentrations were similar with either dosing regimen. The addition of oxandrolone did not affect any of the measured parameters. Oxandrolone coadministration does not alter propranolol's plasma concentration, half-life, or effect on heart rate. This study is registered at clincialtrials.gov: NCT00675714.
4 citations
••
TL;DR: Results suggest that individuals whose Th2 cells predominated may be immunologically controlled by the combination treatment between a Th1 response inducer and a Th2 response inhibitor.
Abstract: Th2 cytokines, commonly detected in burn patients, have been shown as inhibitors for the generation of Th1 cells that are essential for the host's resistance against herpes simplex virus type 1 (HSV-1) infection. In this study, the possibility of immunological treatment through the regulation of Th1/Th2 responses was examined in two kinds of human severe combined immunodeficiency (SCID) chimera models reflecting human immune functions. SCID mice injected with a mixture of PBMC from a healthy donor and Th2 cells experimentally generated from the same healthy PBMC (Th2 SCID chimeras) were more susceptible to HSV-1 infection when compared with SCID mice injected with healthy donor PBMC (healthy SCID chimeras). When Th2 SCID chimeras were individually treated with human IL-12 (hIL-12) or human soluble IL-4 receptor (hsIL-4R), hIFN- was not produced in their sera after antihuman CD3 mAb stimulation. However, hIFN- production in sera of Th2 SCID chimeras treated with the combination therapy of hIL-12 and hsIL-4R was recovered at levels observed in healthy SCID chimeras. When Th2 SCID chimeras infected with HSV-1 were treated with saline, hIL-12, hsIL-4R or a combination of hIL-12 and hsIL-4R, 13%, 13%, 25% or 100% of them survived, respectively. Also, Th1 responses (hIFN- production) were demonstrated in Th2 SCID chimeras that became resistant against HSV-1 infection after the combination treatment. These results suggest that individuals whose Th2 cells predominated may be immunologically controlled by the combination treatment between a Th1 response inducer and a Th2 response inhibitor.
4 citations
Authors
Showing all 250 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert R. Wolfe | 124 | 566 | 54000 |
Csaba Szabó | 123 | 958 | 61791 |
David N. Herndon | 108 | 1227 | 54888 |
Steven E. Wolf | 74 | 419 | 21329 |
Blake B. Rasmussen | 65 | 152 | 18951 |
Marc G. Jeschke | 64 | 174 | 13903 |
Daniel L. Traber | 62 | 629 | 14801 |
Nicole S. Gibran | 60 | 273 | 14304 |
Donald S. Prough | 58 | 508 | 11644 |
David L. Chinkes | 56 | 151 | 11871 |
Labros S. Sidossis | 53 | 224 | 11636 |
Robert E. Barrow | 51 | 130 | 7114 |
Ashok K. Chopra | 49 | 199 | 7568 |
James A. Carson | 49 | 157 | 7554 |
Celeste C. Finnerty | 48 | 172 | 10647 |